tetano
Editor, Senior Moderator
Cureus
. 2023 Mar 20;15(3):e36426.
doi: 10.7759/cureus.36426. eCollection 2023 Mar.
Intractable Neuropathic Pain in COVID-19-Induced Guillain-Barré Syndrome: A Case Report
Stephen Ritter[SUP] 1 [/SUP], Daniel Gable[SUP] 1 [/SUP], Andrew May[SUP] 1 [/SUP], Yousef Darwish[SUP] 1 [/SUP], Tracy Friedlander[SUP] 1 [/SUP]
Affiliations
Abstract
There is limited literature specific to neuropathic pain in coronavirus disease 2019 (COVID-19)-induced acute inflammatory demyelinating polyneuropathy (AIDP). We present a unique case of a 20-year-old vaccinated female with a past medical history of chronic hepatitis B virus and untreated anxiety who presented to the emergency department due to an intractable headache and horizontal diplopia in the setting of active COVID-19 infection. During acute hospitalization, the patient was diagnosed with the Miller-Fisher variant of Guillain-Barré syndrome (GBS), a disease with a known association with COVID-19. While in the ICU, the patient developed severe, 10/10-rated, distal, symmetric burning pain with associated allodynia requiring a multimodal regimen with combinations of intravenous narcotics, neuropathic medications, topical agents, and desensitization training to attempt to control her pain. Rehabilitation psychology was consulted while she was in chronic ventilatory rehabilitation for supplementation of behavioral pain management strategies with pharmacological approaches for continued pain. After several months and completion of a comprehensive inpatient rehabilitation program, the patient was weaned off intravenous narcotics and prescribed oral pain medications. This patient had the optimal response to amitriptyline, which likely aided in the co-treatment of psychological manifestations of COVID-19 and prolonged hospitalization. This study highlights the pathogenicity of COVID-19-induced AIDP, its potential severity, and the importance of a multidisciplinary approach to managing it.
Keywords: allodynia; covid 19; guillain barrè syndrome; miller-fisher syndrome; neuropathic pain.
. 2023 Mar 20;15(3):e36426.
doi: 10.7759/cureus.36426. eCollection 2023 Mar.
Intractable Neuropathic Pain in COVID-19-Induced Guillain-Barré Syndrome: A Case Report
Stephen Ritter[SUP] 1 [/SUP], Daniel Gable[SUP] 1 [/SUP], Andrew May[SUP] 1 [/SUP], Yousef Darwish[SUP] 1 [/SUP], Tracy Friedlander[SUP] 1 [/SUP]
Affiliations
- PMID: 37090295
- PMCID: PMC10115434
- DOI: 10.7759/cureus.36426
Abstract
There is limited literature specific to neuropathic pain in coronavirus disease 2019 (COVID-19)-induced acute inflammatory demyelinating polyneuropathy (AIDP). We present a unique case of a 20-year-old vaccinated female with a past medical history of chronic hepatitis B virus and untreated anxiety who presented to the emergency department due to an intractable headache and horizontal diplopia in the setting of active COVID-19 infection. During acute hospitalization, the patient was diagnosed with the Miller-Fisher variant of Guillain-Barré syndrome (GBS), a disease with a known association with COVID-19. While in the ICU, the patient developed severe, 10/10-rated, distal, symmetric burning pain with associated allodynia requiring a multimodal regimen with combinations of intravenous narcotics, neuropathic medications, topical agents, and desensitization training to attempt to control her pain. Rehabilitation psychology was consulted while she was in chronic ventilatory rehabilitation for supplementation of behavioral pain management strategies with pharmacological approaches for continued pain. After several months and completion of a comprehensive inpatient rehabilitation program, the patient was weaned off intravenous narcotics and prescribed oral pain medications. This patient had the optimal response to amitriptyline, which likely aided in the co-treatment of psychological manifestations of COVID-19 and prolonged hospitalization. This study highlights the pathogenicity of COVID-19-induced AIDP, its potential severity, and the importance of a multidisciplinary approach to managing it.
Keywords: allodynia; covid 19; guillain barrè syndrome; miller-fisher syndrome; neuropathic pain.